| MeSH term | MeSH ID | Detail |
|---|---|---|
| Fibrosis | D005355 | 23 associated lipids |
| Fistula | D005402 | 8 associated lipids |
| Foot Diseases | D005534 | 4 associated lipids |
| Fractures, Open | D005597 | 3 associated lipids |
| Fusobacterium Infections | D005674 | 3 associated lipids |
| Gastritis | D005756 | 27 associated lipids |
| Gastritis, Atrophic | D005757 | 4 associated lipids |
| Gastritis, Hypertrophic | D005758 | 1 associated lipids |
| Gastroesophageal Reflux | D005764 | 10 associated lipids |
| Gastrointestinal Diseases | D005767 | 20 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gibreel A et al. | Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. | 2007 | Antimicrob. Agents Chemother. | pmid:17606685 |
| Maurin M and Raoult D | In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8109928 |
| O'Hara K and Yamamoto K | Reaction of roxithromycin and clarithromycin with macrolide-inactivating enzymes from highly erythromycin-resistant Escherichia coli. | 1996 | Antimicrob. Agents Chemother. | pmid:8849224 |
| la Porte CJ et al. | Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. | 2009 | Antimicrob. Agents Chemother. | pmid:19015362 |
| Goswami S et al. | Anti-Helicobacter pylori potential of artemisinin and its derivatives. | 2012 | Antimicrob. Agents Chemother. | pmid:22687518 |
| Giacometti A et al. | In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. | 2007 | Antimicrob. Agents Chemother. | pmid:17220421 |
| Vermot D et al. | Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis. | 1996 | Antimicrob. Agents Chemother. | pmid:8851620 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Yasuda H et al. | Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. | 1994 | Antimicrob. Agents Chemother. | pmid:8141568 |
| Tomioka H et al. | Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 | Antimicrob. Agents Chemother. | pmid:10582897 |
| Yasuda H et al. | Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8239580 |
| Wakabayashi H et al. | Inhibitory effects of lactoferrin on growth and biofilm formation of Porphyromonas gingivalis and Prevotella intermedia. | 2009 | Antimicrob. Agents Chemother. | pmid:19451301 |
| Inderlied CB et al. | Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. | 1994 | Antimicrob. Agents Chemother. | pmid:7986017 |
| Conte JE et al. | Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. | 1996 | Antimicrob. Agents Chemother. | pmid:8807050 |
| Ferro BE et al. | Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. | 2016 | Antimicrob. Agents Chemother. | pmid:27458221 |
| Nash KA and Inderlied CB | Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. | 1996 | Antimicrob. Agents Chemother. | pmid:8807078 |
| Kamoda O et al. | In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection. | 2006 | Antimicrob. Agents Chemother. | pmid:16940102 |
| Dean NC et al. | Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. | 2006 | Antimicrob. Agents Chemother. | pmid:16569825 |
| Kanamaru T et al. | In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. | 2001 | Antimicrob. Agents Chemother. | pmid:11502514 |
| Moon JE et al. | Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. | 2006 | Antimicrob. Agents Chemother. | pmid:16723556 |
| Burton AJ et al. | Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. | 2015 | Antimicrob. Agents Chemother. | pmid:25824218 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| Beeton ML et al. | Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. | 2009 | Antimicrob. Agents Chemother. | pmid:19273669 |
| Bolhuis MS et al. | Clarithromycin significantly increases linezolid serum concentrations. | 2010 | Antimicrob. Agents Chemother. | pmid:20837753 |
| Tsuda T et al. | Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. | 2008 | Antimicrob. Agents Chemother. | pmid:18212111 |
| Nash KA et al. | A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. | 2009 | Antimicrob. Agents Chemother. | pmid:19171799 |
| Walzer PD et al. | Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. | 1997 | Antimicrob. Agents Chemother. | pmid:9021174 |
| Banerjee DK et al. | Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. | 1997 | Antimicrob. Agents Chemother. | pmid:9021187 |
| Lonks JR and Medeiros AA | High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. | 1993 | Antimicrob. Agents Chemother. | pmid:8239578 |
| Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
| Fong IW et al. | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. | 2002 | Antimicrob. Agents Chemother. | pmid:12121899 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Horgen L et al. | Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium. | 1998 | Antimicrob. Agents Chemother. | pmid:9797242 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Tsaganos T et al. | Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis. | 2016 | Antimicrob. Agents Chemother. | pmid:27044546 |
| Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
| Clark CL et al. | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. | 2007 | Antimicrob. Agents Chemother. | pmid:17876003 |
| Ohtani H et al. | Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. | 2000 | Antimicrob. Agents Chemother. | pmid:10991836 |
| Berg HF et al. | Emergence and persistence of macrolide resistance in oropharyngeal flora and elimination of nasal carriage of Staphylococcus aureus after therapy with slow-release clarithromycin: a randomized, double-blind, placebo-controlled study. | 2004 | Antimicrob. Agents Chemother. | pmid:15504839 |
| Kohno Y et al. | In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. | 2007 | Antimicrob. Agents Chemother. | pmid:17709469 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Bohnert JA et al. | Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. | 2016 | Antimicrob. Agents Chemother. | pmid:26824939 |
| Rastogi N and Labrousse V | Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1828135 |
| Ellis LC et al. | Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. | 1995 | Antimicrob. Agents Chemother. | pmid:8593025 |
| Truffot-Pernot C et al. | Clarithromycin is inactive against Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:8593032 |
| De R et al. | Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. | 2009 | Antimicrob. Agents Chemother. | pmid:19204190 |
| Wolinsky E | Mycobacterium avium strains resistant to clarithromycin and azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8031406 |
| Miltner EC and Bermudez LE | Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. | 2000 | Antimicrob. Agents Chemother. | pmid:10858369 |
| Perronne C et al. | Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1656860 |
| Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
| Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
| Kawai Y et al. | Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. | 2013 | Antimicrob. Agents Chemother. | pmid:23459497 |
| Shinkai M et al. | Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. | 2006 | Antimicrob. Agents Chemother. | pmid:16641444 |
| English ML et al. | Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. | 2012 | Antimicrob. Agents Chemother. | pmid:22290969 |
| Jorgensen JH et al. | Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. | 1991 | Antimicrob. Agents Chemother. | pmid:1834012 |
| Truffot-Pernot C et al. | Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. | 1991 | Antimicrob. Agents Chemother. | pmid:1834015 |
| Ji B et al. | Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. | 2008 | Antimicrob. Agents Chemother. | pmid:18391038 |
| Greendyke R and Byrd TF | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. | 2008 | Antimicrob. Agents Chemother. | pmid:18378709 |
| Fernandez-Martin J et al. | Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. | 1991 | Antimicrob. Agents Chemother. | pmid:1836943 |
| Konstantinidis T et al. | Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps. | 2016 | Antimicrob. Agents Chemother. | pmid:26643338 |
| Portaels F et al. | In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9687409 |
| Ferro BE et al. | Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. | 2016 | Antimicrob. Agents Chemother. | pmid:26643335 |
| Bermudez LE et al. | Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10991834 |
| Goldstein EJ et al. | Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. | 1998 | Antimicrob. Agents Chemother. | pmid:9593139 |
| Wang G et al. | Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. | 2001 | Antimicrob. Agents Chemother. | pmid:11181351 |
| Rastogi N et al. | In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. | 2000 | Antimicrob. Agents Chemother. | pmid:10991870 |
| Spangler SK et al. | Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. | 1998 | Antimicrob. Agents Chemother. | pmid:9593160 |
| Segreti J et al. | In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2952061 |
| Alhajlan M et al. | Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. | 2013 | Antimicrob. Agents Chemother. | pmid:23545534 |
| Benson CA et al. | In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2952063 |
| Gelber RH et al. | Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. | 1991 | Antimicrob. Agents Chemother. | pmid:1648889 |
| Barry AL et al. | In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. | 1987 | Antimicrob. Agents Chemother. | pmid:2952064 |
| Burucoa C et al. | T2182C mutation is not associated with clarithromycin resistance in Helicobacter pylori. | 2005 | Antimicrob. Agents Chemother. | pmid:15673794 |
| Woosley LN et al. | CEM-101 activity against Gram-positive organisms. | 2010 | Antimicrob. Agents Chemother. | pmid:20176910 |
| Bermudez LE et al. | EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium. | 2007 | Antimicrob. Agents Chemother. | pmid:17296742 |
| Chin NX et al. | Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. | 1987 | Antimicrob. Agents Chemother. | pmid:2953303 |
| Rastogi N and Goh KS | Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. | 1992 | Antimicrob. Agents Chemother. | pmid:1482156 |
| Bowie WR et al. | In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:2953304 |
| Rastogi N et al. | Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. | 1992 | Antimicrob. Agents Chemother. | pmid:1482157 |
| Derouin F et al. | Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. | 1992 | Antimicrob. Agents Chemother. | pmid:1482160 |
| Finch R et al. | Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. | 2002 | Antimicrob. Agents Chemother. | pmid:12019085 |
| Prazeres Magalhães P et al. | Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. | 2002 | Antimicrob. Agents Chemother. | pmid:12019131 |
| Floyd-Reising S et al. | In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. | 1987 | Antimicrob. Agents Chemother. | pmid:2955742 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Lee JH et al. | Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. | 2005 | Antimicrob. Agents Chemother. | pmid:15793150 |
| Nash KA | Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. | 2001 | Antimicrob. Agents Chemother. | pmid:11353601 |
| Fernandes PB et al. | Susceptibility testing of macrolide antibiotics against Haemophilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia model. | 1987 | Antimicrob. Agents Chemother. | pmid:2957954 |
| Mor N and Esfandiari A | Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. | 1997 | Antimicrob. Agents Chemother. | pmid:9303411 |
| Polis MA et al. | Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. | 1997 | Antimicrob. Agents Chemother. | pmid:9257746 |
| Walker KJ et al. | Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. | 1994 | Antimicrob. Agents Chemother. | pmid:7811010 |
| Bogdanovich T et al. | Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. | 2006 | Antimicrob. Agents Chemother. | pmid:16495248 |
| Jones RN et al. | Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. | 2010 | Antimicrob. Agents Chemother. | pmid:20660671 |
| Koh WJ et al. | Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. | 2013 | Antimicrob. Agents Chemother. | pmid:23183432 |
| Kosowska-Shick K et al. | Comparative antipneumococcal activities of sulopenem and other drugs. | 2009 | Antimicrob. Agents Chemother. | pmid:19307366 |
| Berti AD et al. | Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. | 2012 | Antimicrob. Agents Chemother. | pmid:22802248 |
| Zhanel GG and Karlowsky JA | In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. | 2009 | Antimicrob. Agents Chemother. | pmid:19139284 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
| Cohen Y et al. | Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. | 1995 | Antimicrob. Agents Chemother. | pmid:7793882 |
| Furney SK et al. | Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793895 |